For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Theravance, Inc.

Calculating rank

USPTO Granted Patents = 386

% Expired Patents = 39.9

CIPO Patents = 25

EPO Patents = 37

Trademarks = 6

Forward Citations = 4,496

Loading Chart...

Loading Chart...

117 inventors (with patents filed for the assignee):

Mathai Mammen (92 out of 104 patents)

Paul Ross Fatheree (90 out of 144 patents)

YongQi Mu (67 out of 95 patents)

4. Seok-Ki Choi (63 out of 76 patents)

5. Daniel D Long (60 out of 104 patents)

6. Yu-Hua Ji (56 out of 58 patents)

7. Craig Husfeld (51 out of 85 patents)

8. Daniel Marquess (51 out of 58 patents)

9. Martin Sheringham Linsell (50 out of 82 patents)

10. Adam D Hughes (46 out of 136 patents)

11. Li Li (40 out of 55 patents)

12. Roland Gendron (40 out of 75 patents)

13. Robert Murray McKinnell (38 out of 73 patents)

14. Edmund J Moran (35 out of 48 patents)

15. Michael Robert Leadbetter (35 out of 66 patents)

Core Competencies:

Biphenyl Compounds

Antihypertensive Agents

Serotonin Reuptake Inhibitors

Mu Opioid Receptor Antagonists

Neprilysin Inhibitors

Quaternary Ammonium Compounds

Aminotetralin Derivatives

Glycopeptide Antibiotics

Dual-acting Agents

Crystalline Forms

Process Preparation

Alkoxyimidazol Compounds

386 patents: Sort by Forward Citations

1. 8754225 - Process for preparing a biphenyl-2-ylcarbamic acid (2014-06-17),

2. 8754223 - Crystalline form of a biphenyl compound (2014-06-17),

3. 8735625 - Dual-acting antihypertensive agents (2014-05-27),

4. 8729119 - Serotonin reuptake inhibitors (2014-05-20),

5. 8716313 - Crystalline forms of a biphenyl compound (2014-05-06),

6. 8703791 - 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists (2014-04-22),

7. 8697724 - Crystalline oxalate salts of a diamide compound (2014-04-15),

8. 8691868 - Neprilysin inhibitors (2014-04-08),

9. 8686184 - Neprilysin inhibitors (2014-04-01),

10. 8664254 - Dual-acting imidazole antihypertensive agents (2014-03-04),

11. 8664242 - 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists (2014-03-04),

12. 8664227 - Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents (2014-03-04),

13. 8658691 - Crystalline forms of a 3-[2-methanesulfonyl-1-(4-trifluoromethyl-phenoxy)ethyl]pyrrolidine compound (2014-02-25),

14. 8658671 - Crystalline form of a quinolinone-carboxamide compound (2014-02-25),

15. 8637676 - Dual-acting benzoimidazole antihypertensive agents (2014-01-28),

Company Overview

Theravance, Inc. is a biopharmaceutical company based in South San Francisco, California, specializing in the development of innovative pharmaceutical compounds. The company focuses on a range of therapeutic areas, particularly in the fields of antihypertensive agents and pain management, leveraging advanced technologies such as biphenyl compounds and mu opioid receptor antagonists. Their research also encompasses neprilysin inhibitors and glycopeptide antibiotics, aiming to address significant unmet medical needs through targeted therapies.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

386 Patents

#3 in South San Francisco, CA

#256 in California

#1,199 in US

#2,402 in the World

South San Francisco, CA, United States of America

Theravance, Inc.

Forward Citations = 4,496

117 inventors:

Mathai Mammen (92 out of 104 patents)

Paul Ross Fatheree (90 out of 144 patents)

YongQi Mu (67 out of 95 patents)

4. Seok-Ki Choi (63 out of 76 patents)

5. Daniel D Long (60 out of 104 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Theravance, Inc.. Retrieved from https://idiyas.com/company/theravance

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…